Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy

J. P. O'Connell, M. G. Kris, Richard J. Gralla, S. Groshen, A. Trust, J. J. Fiore, D. P. Kelsen, R. T. Heelan, R. B. Golbey

Research output: Contribution to journalArticle

215 Citations (Scopus)

Abstract

To determine the frequency and prognostic importance of pretreatment clinical characteristics in patients currently undergoing treatment for stage III non-small-cell lung cancer (NSCLC), data were collected on 378 patients receiving high-dose (120 mg/m2) cisplatin plus vinca alkaloid combination chemotherapy regimens since 1978. Variables analyzed included age, sex, weight loss, performance status, histologic subtype, presence of extrathoracic metastases, number of metastatic organ sites, presence of liver, bone, or brain involvement, prior radiation or surgery, and serum lactate dehydrogenase (LDH). The effect of a major response to chemotherapy on survival was also investigated. Using multivariable analyses, the following were found to be associated with outcome: initial performance status, with patients having a performance status of 80% to 100% having an increased major objective response rate and survival; bone metastases, which were adversely predictive of response rate and survival; elevated serum LDH and male sex, both of which were associated with shortened survival and remission duration; and the presence of two or more extrathoracic metastatic organ sites, which was associated with shorter survival. When major objective response with chemotherapy was included in a conditional multivariable analysis, it was strongly associated with longer median survival. Information from this analysis may be useful when comparing the response data of completed studies in similar patients, in designing future trials, and in the selection of cisplatin plus vinca alkaloid therapy for individual patients with advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)1604-1614
Number of pages11
JournalJournal of Clinical Oncology
Volume4
Issue number11
StatePublished - 1986
Externally publishedYes

Fingerprint

Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Vinca Alkaloids
Survival
L-Lactate Dehydrogenase
Cisplatin
Survival Rate
Neoplasm Metastasis
Bone and Bones
Drug Therapy
Serum
Weight Loss
Radiation
Liver
Brain
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. / O'Connell, J. P.; Kris, M. G.; Gralla, Richard J.; Groshen, S.; Trust, A.; Fiore, J. J.; Kelsen, D. P.; Heelan, R. T.; Golbey, R. B.

In: Journal of Clinical Oncology, Vol. 4, No. 11, 1986, p. 1604-1614.

Research output: Contribution to journalArticle

O'Connell, J. P. ; Kris, M. G. ; Gralla, Richard J. ; Groshen, S. ; Trust, A. ; Fiore, J. J. ; Kelsen, D. P. ; Heelan, R. T. ; Golbey, R. B. / Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 11. pp. 1604-1614.
@article{1f49c23851b94292bb6e7019ef247a55,
title = "Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy",
abstract = "To determine the frequency and prognostic importance of pretreatment clinical characteristics in patients currently undergoing treatment for stage III non-small-cell lung cancer (NSCLC), data were collected on 378 patients receiving high-dose (120 mg/m2) cisplatin plus vinca alkaloid combination chemotherapy regimens since 1978. Variables analyzed included age, sex, weight loss, performance status, histologic subtype, presence of extrathoracic metastases, number of metastatic organ sites, presence of liver, bone, or brain involvement, prior radiation or surgery, and serum lactate dehydrogenase (LDH). The effect of a major response to chemotherapy on survival was also investigated. Using multivariable analyses, the following were found to be associated with outcome: initial performance status, with patients having a performance status of 80{\%} to 100{\%} having an increased major objective response rate and survival; bone metastases, which were adversely predictive of response rate and survival; elevated serum LDH and male sex, both of which were associated with shortened survival and remission duration; and the presence of two or more extrathoracic metastatic organ sites, which was associated with shorter survival. When major objective response with chemotherapy was included in a conditional multivariable analysis, it was strongly associated with longer median survival. Information from this analysis may be useful when comparing the response data of completed studies in similar patients, in designing future trials, and in the selection of cisplatin plus vinca alkaloid therapy for individual patients with advanced NSCLC.",
author = "O'Connell, {J. P.} and Kris, {M. G.} and Gralla, {Richard J.} and S. Groshen and A. Trust and Fiore, {J. J.} and Kelsen, {D. P.} and Heelan, {R. T.} and Golbey, {R. B.}",
year = "1986",
language = "English (US)",
volume = "4",
pages = "1604--1614",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy

AU - O'Connell, J. P.

AU - Kris, M. G.

AU - Gralla, Richard J.

AU - Groshen, S.

AU - Trust, A.

AU - Fiore, J. J.

AU - Kelsen, D. P.

AU - Heelan, R. T.

AU - Golbey, R. B.

PY - 1986

Y1 - 1986

N2 - To determine the frequency and prognostic importance of pretreatment clinical characteristics in patients currently undergoing treatment for stage III non-small-cell lung cancer (NSCLC), data were collected on 378 patients receiving high-dose (120 mg/m2) cisplatin plus vinca alkaloid combination chemotherapy regimens since 1978. Variables analyzed included age, sex, weight loss, performance status, histologic subtype, presence of extrathoracic metastases, number of metastatic organ sites, presence of liver, bone, or brain involvement, prior radiation or surgery, and serum lactate dehydrogenase (LDH). The effect of a major response to chemotherapy on survival was also investigated. Using multivariable analyses, the following were found to be associated with outcome: initial performance status, with patients having a performance status of 80% to 100% having an increased major objective response rate and survival; bone metastases, which were adversely predictive of response rate and survival; elevated serum LDH and male sex, both of which were associated with shortened survival and remission duration; and the presence of two or more extrathoracic metastatic organ sites, which was associated with shorter survival. When major objective response with chemotherapy was included in a conditional multivariable analysis, it was strongly associated with longer median survival. Information from this analysis may be useful when comparing the response data of completed studies in similar patients, in designing future trials, and in the selection of cisplatin plus vinca alkaloid therapy for individual patients with advanced NSCLC.

AB - To determine the frequency and prognostic importance of pretreatment clinical characteristics in patients currently undergoing treatment for stage III non-small-cell lung cancer (NSCLC), data were collected on 378 patients receiving high-dose (120 mg/m2) cisplatin plus vinca alkaloid combination chemotherapy regimens since 1978. Variables analyzed included age, sex, weight loss, performance status, histologic subtype, presence of extrathoracic metastases, number of metastatic organ sites, presence of liver, bone, or brain involvement, prior radiation or surgery, and serum lactate dehydrogenase (LDH). The effect of a major response to chemotherapy on survival was also investigated. Using multivariable analyses, the following were found to be associated with outcome: initial performance status, with patients having a performance status of 80% to 100% having an increased major objective response rate and survival; bone metastases, which were adversely predictive of response rate and survival; elevated serum LDH and male sex, both of which were associated with shortened survival and remission duration; and the presence of two or more extrathoracic metastatic organ sites, which was associated with shorter survival. When major objective response with chemotherapy was included in a conditional multivariable analysis, it was strongly associated with longer median survival. Information from this analysis may be useful when comparing the response data of completed studies in similar patients, in designing future trials, and in the selection of cisplatin plus vinca alkaloid therapy for individual patients with advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0023031031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023031031&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 1604

EP - 1614

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -